Trend
DailyUptrend (confirmed)
4 hourLeaning Bullish
1 hourBullish
15 minBearish
5 minNo data
Daily trend turns down below $84.36
Key levels
Support$84.67
Support$84.36
Latest news & SEC filings
AnalystCantor Fitzgerald Halts Coverage Stance for Crinetics Pharmaceuticals
SEC FilingCrinetics Pharmaceuticals, Inc. filed an insider trading report (Form 4)
All CRNX news →· Healthcare
SEPT Low Target
$72.25
SEPT Mid Target
$85.00
SEPT High Target
$97.75
Analyst Consensus
$85.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRNX.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$77.10
27
Moat Score
NONE
2/9
Piotroski Score
33.0
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
SELLING
0 buys / 3 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| WIERENGA WENDELL | director | Sale | 116,146 | $9.9M | Sep 1, 2026 |
| WIERENGA WENDELL | director | Sale | 5,925 | $504K | Sep 1, 2026 |
| Vivaldi Coelho Rogerio | director | Sale | 13,300 | $1.1M | Sep 1, 2026 |
| Vivaldi Coelho Rogerio | director | Sale | 5,925 | $504K | Sep 1, 2026 |
| Fust Matthew K | director | Sale | 22,836 | $1.9M | Sep 1, 2026 |
| Fust Matthew K | director | Sale | 5,925 | $504K | Sep 1, 2026 |
| Bedrosian Camille L | director | Sale | 16,300 | $1.4M | Sep 1, 2026 |
| Bedrosian Camille L | director | Sale | 5,925 | $504K | Sep 1, 2026 |
| Deardorf Caren | director | Sale | 16,300 | $1.4M | Sep 1, 2026 |
| Deardorf Caren | director | Sale | 5,925 | $504K | Sep 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
640.7%
3yr Revenue CAGR
17.6%
EPS Growth YoY
-34.15%
FCF Growth YoY
-63.9%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for CRNX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:13:35 | $84.97 | 1,000 | $$85K | MIDPOINT |
| 21:10:00 | $84.97 | 5,000 | $$425K | BUY |
| 20:54:54 | $84.95 | 546,360 | $$46.4M | SELL |
| 20:24:48 | $84.95 | 1,391 | $$118K | SELL |
| 20:18:27 | $84.97 | 1,300 | $$110K | BUY |
5 dark pool trades shown · $$47.2M preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Crinetics Pharmaceuticals, Inc. (CRNX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Crinetics Pharmaceuticals, Inc. (CRNX) is at $84.95, up 0.13% (+$0.11) at the Aug 31, 2026 close.
Latest CRNX news — Sep 2, 2026: Cantor Fitzgerald Halts Coverage Stance for Crinetics Pharmaceuticals · Sep 1, 2026: Crinetics Pharmaceuticals, Inc. filed an insider trading report (Form 4)
The average analyst price target for CRNX is $85.00, ranging from $81 to $95, based on 5 analysts. Latest: UBS downgrade on Jul 28, 2026.
Analyst ratings for CRNX: 0 Buy, 6 Hold, 3 Sell — consensus Hold.
CRNX last reported on Aug 3, 2026: EPS -$1.14 vs -$1.24 expected — a beat of 8.1%.
CRNX does not currently pay a dividend.
Support: $84.67, $84.36, $84.00.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Sep 2, 2026: Cantor Fitzgerald Halts Coverage Stance for Crinetics Pharmaceuticals · Sep 1, 2026: Crinetics Pharmaceuticals, Inc. filed an insider trading report (Form 4)